Clinical Trials Logo

Cesarean Section Complications clinical trials

View clinical trials related to Cesarean Section Complications.

Filter by:

NCT ID: NCT03826459 Completed - Clinical trials for Cesarean Section Complications

Preventing Isthmocele After Cesarean Section

(PICS)
Start date: March 5, 2019
Phase: N/A
Study type: Interventional

Cesarean section accounts for nearly 30% of births in Canada, and is the most commonly performed surgery by Obstetrician Gynecologists. Cesarean scar isthmocele, meaning a defect in the uterine wall at the site of a previous uterine incision, is a common complication of this surgery. While most are likely asymptomatic, isthmoceles can lead to major complications in pregnancy (uterine rupture, invasive placentation, cesarean scar ectopic pregnancy) and outside of pregnancy (abnormal uterine bleeding, infertility and pain). Studies have shown that the method used to suture the uterus at the time of a cesarean section may have an impact on the incidence of post-operative isthmocele formation. Our study is a randomized control trial of the impact of locked vs unlocked uterine closure at cesarean section on the incidence of isthmocele formation. Women undergoing cesarean section will be randomized to have either a locked or unlocked uterine closure. They will then return 6 months after their surgery for a transvaginal ultrasound to evaluate the presence or absence of an isthmocele. This study is a pilot trial. The investigators hope to determine the feasibility of completing a large randomized control trial by recording: a) the number of patient who agree to participate in this study, b) the number of patients who receive the correct intervention and, c) the number of patients who return for their post operative ultrasound. The investigators also plan to assess multiple secondary outcomes. First, the goal is to determine the isthmocele incidence within the study subjects of the pilot trial in order to perform a power calculation for a subsequent larger trial in this area. Another goal is to determine if the uterine closure techniques in this study lead to differences in surgical time, blood loss or the need for intra- or post-operative blood transfusion. Last, the study will collect data on the suture material most commonly used in this study to determine if this requires standardization in the subsequent larger trial.

NCT ID: NCT03824314 Completed - Clinical trials for Cesarean Section Complications

Effect of Adding Midazolam Versus Fentanyl to Intrathecal Levobupivacaine in Patients Undergoing Caesarean Section

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

The aim of this study is to compare the effects of intrathecal levobupivacaine plus midazolam and levobupivacaine plus fentanyl in patients undergoing caesarean section to get a prolonged postoperative analgesic effect and less side effects

NCT ID: NCT03818009 Completed - Clinical trials for Cesarean Section Complications

Effect of General Anesthesia on Early Postoperative Cognitive Function in Cesarean Section

Start date: January 14, 2019
Phase:
Study type: Observational

Cognitive dysfunction is the impairment of the mental process of perception, memory and information processing. The preoperative cognitive state is important, as mild cognitive impairment may be worsened following a cesarean section. Our study will aim to assess the incidence of early cognitive dysfunction after elective and emergent cesarean section under general anesthesia.

NCT ID: NCT03816293 Completed - Obesity Clinical Trials

SUpPress SSI - Single Use Negative Pressure Wound Therapy (NPWT) to Reduce Surgical Site Infections

SUpPressSSI
Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Our goal is to provide data that will give surgeons and hospitals clear recommendations on the use of NPWT for Cesarean section, abdominal hysterectomy and colon surgeries in patients with diabetes and/or obesity. We also want to understand the patient experience with the dressing so that we can provide information that will enable clinicians to remove barriers to NPWT use. Additionally, we are seeking to use automated electronic medical record decision support to identify patients that will benefit most from the NPWT.

NCT ID: NCT03815877 Completed - Clinical trials for Cesarean Section Complications

The Effect of Caffeine Ingestion in Prevention of Postoperative Ileus After Caesarean Section.

Start date: January 17, 2018
Phase: N/A
Study type: Interventional

Many trials have been made to prevent paralytic ileus , including administration of prokinetic drugs , early resumption of feeding, gum chewing and adequate pain control. Unfortunately, none of these strategies has been completely successful. Recently the effect of caffeine on prevention of postoperative ileus after caesarian section was researched. That's why this study is designed to determine the efficacy of caffeine in prevention of postoperative ileus after caesarean section.

NCT ID: NCT03793153 Completed - Clinical trials for Cesarean Section Complications

A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss

Start date: December 19, 2018
Phase: N/A
Study type: Interventional

Study aim to evaluate the efficacy and safety of a novel technique of UTERINE COOLING during repeated cesarean section (CS) in reducing blood loss, and record any adverse effects following it.

NCT ID: NCT03792906 Completed - Clinical trials for Cesarean Section Complications

Comparison of Two Norepinephrine Bolus Doses for Management of Post-spinal Hypotension During Cesarean Delivery

Start date: January 18, 2019
Phase: Phase 4
Study type: Interventional

In this study the investigators will compare two doses of norepinephrine bolus (6 mcg and 10 mcg) in management of maternal hypotensive episode after subarachnoid block during Cesarean delivery.

NCT ID: NCT03778242 Completed - Clinical trials for Cesarean Section Complications

Tranexamic Acid in Pregnant Women Undergoing Cesarean Section.

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Purpose to evaluate the effects of topical tranexamic acid (TA) on reducing post-partum hemorrhage in pregnant women with hemorrhagic cesarean section

NCT ID: NCT03732404 Completed - Clinical trials for Cesarean Section Complications

Oral Preoperative Carbohydrate on Early Postoperative Outcome After Cesarean Section

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Preoperative carbohydrate treatments have been widely adopted as part of enhanced recovery after surgery (ERAS) or fast-track surgery protocols. Although fast-track surgery protocols have been widely investigated and have been shown to be associated with improved postoperative outcomes, some individual constituents of these protocols, including preoperative carbohydrate treatment, have not been subject to such robust analysis.

NCT ID: NCT03710330 Completed - Clinical trials for Cesarean Section Complications

Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section

Start date: November 1, 2018
Phase: Phase 4
Study type: Interventional

The aim of the study is to determine, out of two doses (a standard and a low dose) compared to placebo, the optimal and minimal dose of an intravenously administered single bolus of tranexamic acid(TA) to reduce blood loss when administered during cesarean section(CS). Tranexamic acid is an antifibrinolytic agent, which causes a reversible and competitive blockade of the lysine binding sites on plasminogen molecules. It is a synthetic analog of the amino acid lysine and its action is to reduce blood loss. TA is widely in use in the field of obstetrics. Both antepartum and postpartum hemorrhage(PPH) is being treated by TA extensively. One study demonstrated for the first time that TA administered to women with overt PPH decreases blood loss and maternal morbidity. Prevention of PPH is another indication where TA has been used. Varied doses of TA ranging from 1 mg/kg to more than 100 mg/kg have been used in various surgeries. Even in studies involving CS, the doses used were either a bolus of 1 gm or 10 mg/kg intravenously. The dose of 1 g or 10 mg/kg is commonly used prophylactically before CS, Because of the lack of data on lower doses and TA pharmacokinetics, a low 0.5-g dose should be tested.